In­ovio's Covid-19 vac­cine stud­ies just hit a brick wall at the Pen­ta­gon. Are oth­er hope­fuls in trou­ble?

In­ovio re­ceived some harsh news from the Pen­ta­gon on Fri­day re­gard­ing its Covid-19 vac­cine pro­gram, and it could prove fore­bod­ing to oth­er mid-stage play­ers in the space.

The US De­part­ment of De­fense has scut­tled fund­ing for In­ovio’s Phase III Covid-19 vac­cine tri­al, In­ovio said in a press re­lease, but will con­tin­ue to fund the study’s Phase II seg­ment. Fri­day’s move comes as a re­sult of a grow­ing avail­abil­i­ty of au­tho­rized vac­cines in the US, In­ovio said the de­part­ment com­mu­ni­cat­ed to them. End­points News has reached out to DoD for com­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER